deposition

L-Ascorbic acid (Vitamin C) is a natural product that is a potent reducing agent and antioxidant. L-Ascorbic acid functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen. L-Ascorbic acid is used in the treatment of scurvy.

TB-500 is a synthesised peptide, essentially a short-chain version of the naturally occurring Thymosin Beta-4.

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.

Ono-3307 mesylate is a protease inhibitor with inhibitory effects on a variety of proteases.Ono-3307 mesylate has significant protective effects against liver injury in rats and inhibits the deposition of radiofibrillar proteins in the kidneys and lungs.PF-184298 is a protease inhibitor with potential antioxidant effects in plasma and adipose tissue.PF-184298 can be used in the study of pancreatitis.

safironil is a novel antifibrotic compound and a competitive inhibitor of collagen synthesis. safironil inhibited in vitro experiments on fibroblast activation monitored by collagen I mRNA or smooth muscle alpha-actin levels, and fibrogenesis as judged by type I and type III collagen and laminin production. safironil had no effect on the size of liver granulomas without altering total hydroxyproline, but altered the pattern of fibrosis by increasing type III and decreasing type I collagen deposition.

Pidobenzone is a melanin synthesis inhibitor that blocks melanin deposition, eliminates melasma and brightens skin.

Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis.

Pro-xylane (Hydroxypropyl tetrahydropyrantriol) is a C-glycoside, a xylose derivative, that stimulates the production of glycosaminoglycans (GAGs) and heparan sulfate proteoglycans (HSPGs) and induces a higher deposition of proteins in basement membranes and dermal-epidermal junctions (DEJs). Pro-xylane is used to maintain skin elasticity and improve skin aging.

cis-L-Hydroxyproline inhibits the synthesis and extracellular deposition of collagen. The growth inhibition of pancreatic cancer cells induced by the Hyp isomer could be due to endoplasmatic reticulum stress.

Endosidin 7, a specific inhibitor of callose synthase, organizes callose deposition during plant cytoplasmic division without affecting endosomal transport during interphase or cytoskeletal organization, preventing late cytokinesis.

Qingyangshengenin B (Otophylloside B) is a C-21 steroidal glycoside isolated from Qingyangshen. Qingyangshengenin B protects against Aβ toxicity, which decreases Aβ deposition by decreasing the expression of Aβ at the mRNA level. Qingyangshengenin B has antiepileptic and anti-aging effects, it can extend lifespan, increase heat stress-resistance, delay body paralysis, and increase the chemotaxis response in C. elegans models of Alzheimer's disease. Otophylloside B can suppress the seizure-like locomotor activity caused by pentylenetetrazole in zebrafish.

Cirsimarin (Cirsitakaoside) is a flavonoid isolated from Microtea debilis. It shows a potent antilipogenic effect and decreases adipose tissue deposition in mice. Cirsimarin has antagonist activity on the adenosine A1 receptor and inhibitory effect on phosphodiesterase.

Gamma-secretase modulator 2 is a potent, selective compound for the treatment of Alzheimer's disease, specifically designed to modulate γ-secretase activity. This modulation selectively attenuates the production of Aβ(1-42), addressing diseases associated with Aβ deposition in the brain, particularly Alzheimer's disease.

MRS1845 is an ORAI1 inhibitor and calcium entry (SOCE) blocker that blocks VP-induced SOCE, OS, and Ca(2+) deposition.

Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway. Fluorofenidone is an analogue of AMR69. Which displays equivalent lower toxicity, antifibrotic activity, and longer half-life.

Complement factor D-IN-1 is a potent and selective small-molecule reversible Factor D inhibitor, with IC50 values of 0.006 μM in the FD Thioesterolytic Fluorescent Assay and 0.05 μM in the MAC Deposition Assay.

PXS-4787 hydrochloride is a specific and potent pan-lysyl oxidase inhibitor that effectively eliminates the activity of lysyl oxidase. It exhibits varying IC50 values against different forms of the enzyme, including 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), and 0.2 μM (rh LOXL4). In addition, PXS-4787 hydrochloride reduces the deposition and cross-linking of collagen I secreted by human fibroblasts.

Isobutylamido thiazolyl resorcinol is a tyrosinase (Tyrosinase) inhibitor that prevents pigment deposition induced by ultraviolet radiation.

Simufilamum (also known as PTI-125) is an oral small-molecule compound candidate that targets altered conformations of filamin A. It binds and reverts the misfolded filamin A in the brains of Alzheimer's disease patients, thereby slowing the disease's pathological progression. Additionally, PTI-125 reduces tau protein hyperphosphorylation, decreases Aβ42 aggregation and deposition, neurofibrillary tangles, and neuroinflammation. The compound demonstrates concentration-dependent efficacy in vitro, starting at 1 picomolar (pM), in both control groups and post-mortem hippocampal slices from Alzheimer's disease (AD) patients. PTI-125 is the first therapeutic candidate to preferentially bind and reverse pathogenic protein conformations.

SKLB102 exhibits high affinity for PPARγ. It has a potent ability to reduce fat deposition and protect the liver from non-alcoholic fatty liver disease (NAFLD) by regulating adipokine expression and preventing insulin resistance.

TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor utilized in idiopathic pulmonary fibrosis research. It demonstrates antifibrotic activity in vitro (IC50 = 0.51 μM) by inhibiting the TGF-β/Smads and MAPK pathways, thereby affecting the expression of fibrosis markers collagen I and α-SMA. In vivo, TRPV1-IN-3 significantly reduces collagen deposition in lung tissue, improves alveolar structure, and increases survival rates in mice with Bleomycin-induced pulmonary fibrosis.

ATX-IN-1 (compound 35) is an ATX inhibitor with an IC50 of 0.7 nM, demonstrating anti-inflammatory properties. It effectively suppresses the TGF-β/Smad pathway and reduces collagen deposition, alleviating fibrosis in a Bleomycin-induced mouse model. This compound also exhibits good oral bioavailability (F=69.5%) and microsomal stability.

5-HT2B antagonist-2 (Compound 19c) is a 5HT2B receptor antagonist with an IC50 of 1.09 nM. It effectively downregulates the expression of fibrosis-related genes α-SMA, Timp1, Col1a1, and Col3a1, significantly reducing cellulose deposition. In a CCl4-induced liver fibrosis mouse model, it decreases the fibrotic area and inhibits the progression of fibrosis. This compound is useful for research into immune-inflammatory related diseases, particularly pulmonary fibrosis.

Win 45164 is an orally active ligand for the glucocorticoid receptor (Glucocorticoid Receptor), exhibiting activity that inhibits the pituitary-adrenal axis. It enhances liver glycogen deposition and thymolysis in adrenalectomized male rats. Additionally, Win 45164 possesses anti-inflammatory properties and is applicable in research related to inflammation and neurological disorders.